Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biolik Tuberculin PPD-L is a diagnostic reagent developed by Biolik Biopharmaceutical for the detection of tuberculosis infection. The active ingredient is allergen-tuberculoprotein, a purified protein derivative (PPD) derived from heat-killed cultures of human and bovine *Mycobacterium tuberculosis*. It is administered intradermally via the Mantoux test. The reagent works by triggering a delayed-type hypersensitivity (Type IV) reaction in individuals who have been previously sensitized to the bacteria through natural infection or BCG vaccination. This reaction is characterized by local skin inflammation, induration, and papule formation at the injection site. It is primarily used for diagnosing latent tuberculosis infection, screening high-risk populations, and determining the necessity of BCG vaccination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biolik Tuberculin PPD-L.